Active Pharmaceutical Ingredient (API) manufacture

A dedicated facility capable of small scale manufacture of active pharmaceutical ingredients for early stage clinical studies.

Based at the Queen's Medical Research Institute, all manufacturing takes place in compliance with Eudralex Volume 4, GMP part II.

This facility can also perform API and final liquid product stability studies and supportive analytical services.

To date, this facility has successfully manufactured 3 API’s for early stage clinical studies and provided associated stability and analytical packages for these agents. Facilitating rapid translation into man by manufacturing in-house, mitigating the risks and costs associated with outsourced manufacture.